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Granulocyte-colony stimulating factor (G-CSF) producing pancreatic cancers are extremely rare. These tumors have an
aggressive clinical course but no established treatment. We encountered a patient with a G-CSF-induced pancreatic
cancer who was treated by surgical resection, followed by steroid treatment and chemotherapy. A 68-year-old Asian
male presented at a local hospital with a 3-month history of fever, loss of appetite, and 10-kg weight loss. Laboratory
data showed leukocytosis and elevation of C-reactive protein. Computed tomography (CT) revealed a 50-mm mass in
the tail of the pancreas, but no signs of infective foci. He was transferred to our hospital for further evaluation. Contrast-
enhanced CT showed rapid growth of this tumor over 1 week, and 18 F-2-fluoro-2-deoxyglucose positron-emission
tomography/computed tomography (FDG PET/CT) showed FDG accumulation in the tail of the pancreas (SUV max,
17.1) but at no other sites in his body. Magnetic resonance imaging showed a heterogeneous mass, similar to that
observed by CT. Three weeks later, the patient underwent a distal pancreatectomy with splenectomy. The resected
specimen was 154 mm in diameter, a threefold increase from the initial image. Histopathological examination identified
the tumor as an anaplastic carcinoma of the pancreas. Following surgery, his leukocyte count and body temperature
were reduced. He recovered well and was discharged from our hospital on postoperative day 18. Immunohistochemical
expression of G-CSF in the resected specimen and elevated serum G-CSF concentration confirmed that the mass was a
G-CSF producing anaplastic carcinoma of the pancreas. Subsequently, the patient experienced a high fever and loss of
appetite. CT showed recurrence of cancer in the abdominal cavity, for which he was started immediately on tegafur-
gimeracil-oteracil potassium combination S-1 and steroid. Unfortunately, he died on postoperative day 83. To our
knowledge, this patient was the first with a G-CSF producing anaplastic carcinoma of the pancreas to be treated by
surgical resection, steroid and adjuvant chemotherapy.
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Since the first description of a granulocyte-colony stimu-
lating factor (G-CSF) producing lung cancer [1], there
have been many reports of such tumors. In contrast, fewer
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provided the original work is properly creditedespecially pancreatic cancers, have been described. The
prognosis of patients with G-CSF producing pancreatic
cancers is very poor [2–7]. Of the patients reported in the
English language literature, only three underwent surgical
operations [5–7]. To date, no standardized treatment has
been established. Most patients with G-CSF producing
pancreatic cancers have been treated by surgical resection
or chemotherapy, not both, with others only receiving pal-
liative care. We describe a patient with a G-CSF produ-
cing pancreatic cancer who underwent surgery followed
by adjuvant chemotherapy.icle distributed under the terms of the Creative Commons Attribution License
hich permits unrestricted use, distribution, and reproduction in any medium,
.
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A 68-year-old Asian male presented at a local hospital
with a 3-month history of high fever, loss of appetite, and
10-kg weight loss. He had no relevant medical history. La-
boratory data showed leukocytosis, with a leukocyte count
of 17,500/mm3, and an elevated serum C-reactive protein
(CRP) concentration of 13.2 mg/dl. Computed tomog-
raphy (CT) showed a mass of 50 mm in diameter at the
tail of the pancreas. One week later, during which his
symptoms had continued, he was transferred to our hos-
pital for further examination.
Blood chemical findings in our hospital showed a
leukocyte count of 14,900/mm3 and a CRP concentra-
tion of 13.5 mg/dl. His serum concentrations of aspar-
tate aminotransferase, alanine aminotransferase, lactate
dehydrogenase, creatinine, and amylase were within nor-
mal levels, but his serum alkaline phosphatase, leucine
aminopeptidase, and gamma-glutamyl transpeptidase
concentrations were elevated to 979, 125, and 266 U/l,
respectively. Serum levels of carcinoembryonic antigen
and pancreas cancer-associated antigen DUPAN-2 were
within normal limits, whereas his carbohydrate antigen
19–9 concentration was elevated at 118.0 U/ml. Bac-
teriological examination showed no signs of infection.
Contrast-enhanced CT showed a heterogeneously
stained tumor, 72 mm in diameter, at the tail of the pancreas
(Fig. 1). 18 F-2-fluoro-2-deoxyglucose positron-emission tom-
ography/computed tomography (FDG PET/CT) showed
FDG accumulation in the tail of the pancreas (SUV
max, 17.1), but at no other sites in his body (Fig. 2).
Abdominal T2-weighted magnetic resonance imaging,Fig. 1 Contrast-enhanced CT on the day of first visit to our hospital, showi
the pancreas. a plain, b arterial phase, c portal phaseperformed 14 days after contrast-enhanced CT, showed a
heterogeneous mass at the tail of the pancreas (Fig. 3); the
tumor was twice as large as in the initial CT image. Dilata-
tion of the main pancreatic and bile ducts was not detected
(Fig. 3). Gastrointestinal endoscopy showed no signs of
malignancy.
The rapid growth of the tumor, along with the continu-
ous high fever, elevated leukocyte count, and elevated CRP,
in the absence of infection, suggested that the mass was a
G-CSF producing pancreatic cancer. The rapid growth of
the tumor limited the time required to make a differential
diagnosis. We therefore decided to resect the tumor, basing
subsequent treatment on histopathological diagnosis. Three
weeks after first presenting at our hospital, the patient
underwent a distal pancreatectomy with splenectomy.
Examination of frozen sections of the tumor indicated that
it was an adenocarcinoma. There was no evidence of lymph
node swelling or peritoneal dissemination. Intraoperative
ultrasonography showed no space occupying lesion in the
liver. The diameter of the resected specimen was 154 mm,
three times as large as in the initial image (Fig. 4). Macro-
scopically curative resection was performed, despite the
tumor invading the transverse mesocolon. The patient’s
leukocyte count rapidly decreased from 26,800/mm3 on the
day before the operation to 5,100/mm3 on postoperative
day three, and his body temperature was rapidly reduced
soon after the operation. He recovered well and was dis-
charged from our hospital 2 weeks after the operation.
Histopathological examination identified the tumor as an
anaplastic carcinoma of the pancreas, composed of a ductal
carcinoma component, along with bizarre giant cells andng a heterogeneously stained tumor, 72 mm in diameter, at the tail of
Fig. 2 FDG PET 18 F-2-fluoro-2-deoxyglucose positron-emission tomography/computed tomography (FDG PET/CT) showed FDG accumulation in
the tail of the pancreas (SUV, 17.1)
Fig. 3 Abdominal magnetic resonance imaging (MRI) 14 days after contrast-enhanced CT. a T1 weighted MRI, b T2 weighted MRI image, showing
a heterogeneous mass, 100 mm in diameter, at the tail of the pancreas
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Fig. 4 Macroscopic findings. The resected specimen was a large tumor (154 mm in diameter) at the tail of the pancreas, invading the
transverse mesocolon
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examination of the resected specimen showed G-CSF
expression (Fig. 5b–d), which, together with his preopera-
tive serum G-CSF concentration of 355 pg/ml (normal
range <39 pg/ml), confirmed that the tumor was a G-CSF
producing pancreatic cancer. On postoperative day 48, the
patient returned to our hospital with a high fever and
loss of appetite. CT showed tumor recurrence. He was
started immediately on tegafur-gimeracil-oteracil potassium
combination S-1 (TS-1) and steroid (betamethasone) 1 mg/
day. Despite administration of steroid and nonsteroidal
anti-inflammatory drugs, high fever remained unaltered.
Serial leukocyte counts, granulocyte counts, and body
temperature are shown in Fig. 6. Two weeks after startingFig. 5 Microscopic findings. a The tumor was pathologically diagnosed as an a
(b), spindle tumor cells (c), and moderately differentiated ductal carcinoma (d) (
(G-CSF) immunohistochemistry in the cytoplasm of formalin-fixed paraf
composed of bizarre, multinucleated giant cells that contain abundant
contained variable numbers and sizes of nuclei. Numerous mitoses were easily
neutrophils. c Spindle-cell component resembling a sarcoma, with cells
was less pleomorphism than in pleomorphic tumor cells, whereas significant atyon TS-1, he was admitted to our hospital. Contrast-
enhanced CT showed peritoneal dissemination and liver
metastases (Fig. 7). His leukocyte count and serum CRP
concentration increased. He was continued on steroid and
TS-1 for 3 weeks, but his condition worsened, and he died
on postoperative day 83.
Conclusions
This report describes a very rare case of G-CSF produ-
cing anaplastic carcinoma of the pancreas. To date, only
six G-CSF producing pancreatic cancers have been re-
ported in the English language literature [2–7], including
three anaplastic carcinomas, one adenosquamous carcin-
oma, and two poorly differentiated adenocarcinomas.naplastic carcinoma of the pancreas, containing pleomorphic tumor cells
H& E × 40). b-d Positive staining of granulocyte-colony stimulating factor
fin-embedded specimen (×400). b Pleomorphic tumor cell variant,
eosinophilic cytoplasm. The nuclei were large, hyperchromatic, and
identified, including bizarre mitoses. These cells were suspended in a sea of
arranged in fascicles, sometimes in a herringbone pattern. There





















Fig. 6 Serial leukocyte counts, granulocyte counts, and body temperature in this patient. Elevated leukocyte and granulocyte counts were reduced
immediately after surgery. Body temperature was also reduced rapidly soon after the operation. These parameters were all elevated after tumor recurrence
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sible its resection despite its very rapid growth. The
combination of surgery, chemotherapy, and steroid treat-
ment in this patient did not improve his outcome.
Following the first report of a G-CSF producing tumor in
a patient with lung cancer [1], G-CSF producing tumors
were reported in various organs [8–10]. G-CSF producing
pancreatic cancers account for 6.8 % of all G-CSF produ-
cing tumors [11]. Patients with G-CSF producing tumors
have elevated serum G-CSF and increased leukocyte
counts, which are reversed by tumor resection. Moreover,
G-CSF is expressed in the resected specimen, as shown by
immunohistochemistry (IHC) and/or reverse-transcriptase
polymerase chain reaction. Our patient met all of these
criteria for a G-CSF producing tumor. Furthermore,
leukocytosis recurred at the time of tumor recurrence. Only
one other patient with a G-CSF producing pancreaticFig. 7 Contrast-enhanced CT at recurrence on postoperative day 36,
showing peritoneal dissemination and liver metastasestumor who underwent surgical resection was found to have
tumor G-CSF expression by IHC. The other five patients
underwent either resection or IHC.
Microscopic examination of this tumor showed that it
was an anaplastic carcinoma of the pancreas. Anaplastic
carcinoma of the pancreas, first described in 1954 [12],
can be classified into the following four types: 1) giant
cell type; 2) osteoclast-like giant cell type/giant cell carcin-
oma of osteoclastoid type; 3) pleomorphic type; and 4)
spindle-cell type [13]. The tumor in our patient was the
pleomorphic type, but also contained other cell types
(Fig. 5a). Bizarre giant cell and spindle-cell components
could be differentiated from the ductal carcinoma compo-
nent immunohistochemically, G-CSF is expressed in bizarre
giant cell and spindle-cell cytoplasm, as in moderately dif-
ferentiated ductal carcinoma cells (Fig. 5a–d). Only 0.25 %
of all pancreatic cancers are anaplastic carcinomas [14].
The mean age of these patients has been reported to be
61.1 years, with a male-to-female ratio of 24:1 and a mean
survival of 2–7 months [15–17]. Patients with G-CSF pro-
ducing anaplastic carcinomas were reported to be of mean
age 64 years, with a male-to-female ratio of 3:4, and a mean
survival time of 85 days [18]. IHC in our patient
showed G-CSF expression by various types of cells.
KRAS mutant allele-specific imbalance has been re-
ported to correlate with progression to undifferenti-
ated carcinoma of the pancreas [19], and expression of
granulocyte/macrophage colony stimulating factor
(GM-CSF) to correlate with KRAS mutations in pan-
creatic tumors [20]. G-CSF producing tumors may be
affected by GM-CSF.
Growth of this tumor is very rapid, precluding surgical
resection in many patients. The tumor in our patient
was resected because we suspected that it was an early
stage cancer. At resection, the tumor was three times as
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we waited the normal 1–2 months, the tumor could not
have been resected.
The prognosis of patients with G-CSF producing pan-
creatic cancer is poor, the longest overall survival time
being 270 days after initial consultation [21]. The mean
overall survival from detection to death has been re-
ported to be 81.2 days [3]. Treatments reported for this
type of cancer include surgical resection [5, 7] and
chemotherapy [22], with some patients eligible only for
palliative care. Our patient underwent surgical resection
followed by treatment with tegafur-gimeracil-oteracil po-
tassium combination S-1 (TS-1) and steroid. Although
TS-1 treatment was reported to reduce FDG accumula-
tion, that patient survived only 88 days [22]. TS-1 plus
gemcitabine chemotherapy and steroid reduced the
leukocyte count in one patient [23]. Our patient was
administered steroid (betamethasone) to reduce fever,
enhance appetite, and suppress G-CSF and IL-6 expres-
sion. Although this patient experienced a transient in-
crease in appetite, his high fever and tumor growth
continued, and leukocytosis did not improve, suggesting
that surgical resection followed by TS-1 and steroid was
ineffective.
In summary, surgical resection, followed by steroid
plus standard adjuvant chemotherapy, was not effective
in this patient with a G-CSF producing anaplastic car-
cinoma of the pancreas. New treatment strategies are
needed for these patients.
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